Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months

Overview of attention for article published in BMC Neurology, April 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 1 news story.

This article was originally published here BMC Neurol. 2022 Apr 15;22(1):143. doi: 10.1186/s12883-022-02656-8.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.